A Study in Myeloproliferative Disorders

Status Completed

Clinical Trial Summary

The purpose of this study is to find out the safe dose range of the study drug in patients with myeloproliferative disorders.

Clinical Trial Description

The purpose of the study is to learn:

1. How much and how often LY2784544 should be given to patients

2. What is the safety profile of LY2784544 and any side effects that might be associated with it

3. How LY2784544 is taken up, distributed, broken down, and passed out of your body

4. Whether LY2784544 can help patients with myeloproliferative disorders

5. If any markers in the blood (biomarkers) can identify patients who will respond better to the study drug.

The planned duration of the study is not fixed. The length of time patients participate in the study will be determined by the investigator/study doctor.

Part A of the study is to determine the dose of the study drug. Part A is divided into two sections, A1 and A2. In Part A1, patients will be given study drug without a lead-in period. In Parts A2 and B, patients will have a lead-in period of 2 or 4 weeks with a low dose of LY2784544 prior to taking a higher dose of LY2784544. Part B of the study is to confirm the safety of the dose and schedule. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01134120
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 1
Start date	April 2010
Completion date	February 22, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01178281` - Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence	Phase 3
Not yet recruiting	`NCT06327100` - Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)	Phase 2
Active, not recruiting	`NCT00095784` - Decitabine in Treating Patients With Myelofibrosis	Phase 2
Recruiting	`NCT02897297` - Myeloproliferative Neoplastic Diseases Observatory From Brest
Terminated	`NCT02091752` - A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)	Phase 2
Completed	`NCT01445769` - Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis	Phase 2
Completed	`NCT01233921` - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	N/A
Unknown status	`NCT01298934` - LBH589 (Panobinostat) for the Treatment of Myelofibrosis	Phase 1/Phase 2
Terminated	`NCT00387426` - Sunitinib in Treating Patients With Idiopathic Myelofibrosis	Phase 2
Completed	`NCT05044026` - A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis
Active, not recruiting	`NCT03952039` - An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib	Phase 3
Active, not recruiting	`NCT02530619` - Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia	N/A
Completed	`NCT01588015` - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	Phase 1
Completed	`NCT01731951` - Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis	Phase 2
Not yet recruiting	`NCT06468033` - P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk	Phase 3
Completed	`NCT01371617` - A Phase 2 Study With IPI-926 in Patients With Myelofibrosis	Phase 2
Active, not recruiting	`NCT02251821` - JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis	Phase 2
Active, not recruiting	`NCT04446650` - A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)	Phase 1/Phase 2
Completed	`NCT01981850` - A Phase 2 Study of RO7490677 In Participants With Myelofibrosis	Phase 2
Withdrawn	`NCT04283526` - Study of Select Combinations in Adults With Myelofibrosis	Phase 1